PureTech Health/$PRTC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About PureTech Health
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Ticker
$PRTC
Sector
Primary listing
Employees
56
Headquarters
Website
PureTech Health Metrics
BasicAdvanced
$394M
86.81
$0.20
0.82
-
Price and volume
Market cap
$394M
Beta
0.82
52-week high
$22.40
52-week low
$13.30
Average daily volume
2.4K
Financial strength
Current ratio
8.487
Quick ratio
8.353
Long term debt to equity
38.476
Total debt to equity
44.326
Profitability
EBITDA (TTM)
-115.718
Gross margin (TTM)
-763.71%
Net profit margin (TTM)
792.96%
Operating margin (TTM)
-1,837.01%
Effective tax rate (TTM)
8.76%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-12.95%
Return on equity (TTM)
9.44%
Valuation
Price to earnings (TTM)
86.808
Price to revenue (TTM)
656.119
Price to book
0.79
Price to tangible book (TTM)
0.79
Price to free cash flow (TTM)
-41.803
Free cash flow yield (TTM)
-2.39%
Free cash flow per share (TTM)
-0.419
Growth
Revenue change (TTM)
1,265.60%
Earnings per share change (TTM)
-166.49%
3-year revenue growth (CAGR)
-29.94%
10-year revenue growth (CAGR)
-6.16%
3-year earnings per share growth (CAGR)
58.35%
10-year earnings per share growth (CAGR)
-3.53%
What the Analysts think about PureTech Health
Analyst ratings (Buy, Hold, Sell) for PureTech Health stock.
Bulls say / Bears say
Deupirfenidone (LYT-100) achieved statistically significant results in delaying IPF progression (hazard ratio 0.439; p = 0.0023) and maintained stable lung function over 52 weeks, supporting advancement to Phase 3.
PureTech intends to meet with the FDA before the end of Q3 2025 to finalize the Phase 3 trial design for deupirfenidone, demonstrating a clear regulatory strategy and advancing timeline.
The company’s R&D platform has generated 29 therapeutic candidates, three of which are already FDA-approved, indicating a strong and promising innovation pipeline.
H1 2025 operating expenses of $49.8 million will likely require PureTech to seek external funding for pivotal Phase 3 trials, which could dilute shareholder value.
Contract revenues for H1 2025 totaled only $1.85 million, far below operating costs, highlighting continued cash burn and revenue shortfall.
Shares have dropped 7.37% year-to-date, trading near a 52-week low of $13.30, signaling market skepticism about the timing and outcome of major clinical milestones.
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
PureTech Health Financial Performance
Revenues and expenses
PureTech Health Earnings Performance
Company profitability
PureTech Health News
AllArticlesVideos
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
Business Wire3 weeks ago
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
Business Wire1 month ago
PureTech Health plc – Half-Year Report
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PureTech Health stock?
PureTech Health (PRTC) has a market cap of $394M as of November 10, 2025.
What is the P/E ratio for PureTech Health stock?
The price to earnings (P/E) ratio for PureTech Health (PRTC) stock is 86.81 as of November 10, 2025.
Does PureTech Health stock pay dividends?
No, PureTech Health (PRTC) stock does not pay dividends to its shareholders as of November 10, 2025.
When is the next PureTech Health dividend payment date?
PureTech Health (PRTC) stock does not pay dividends to its shareholders.
What is the beta indicator for PureTech Health?
PureTech Health (PRTC) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.